Special Issue

Personalized Treatment Strategy in Early Breast Cancer

Message from the Guest Editor

Treatment for early breast cancer usually involves a combination of surgery, radiation therapy, chemotherapy, hormone therapy, and/or HER2-targeted therapy based on the breast cancer subtype. Neoadjuvant therapy (chemotherapy, HER2-targeted therapy, or endocrine therapy) is a well-known treatment strategy mainly in cases of locally advanced tumor, as well as triple-negative or HER2 positive breast cancer. The timing of chemotherapy around surgery does not affect survival outcome, but it is well known that patients who achieve a complete pathological response have better long-term outcomes. Moreover, neoadjuvant chemotherapy is an optimal setting for studying both breast cancer biology and the upcoming drug resistance due to the pressure of therapies. Finally, based on tumor response to preoperative therapy, adjuvant treatment can be tailored for every patient. This Special Issue will highlight the current state of the art in neoadjuvant treatment of breast cancer and will focus on the possibility of tailoring the best treatment strategy for every patient based on tumor biology and/or patients' characteristics.

Guest Editor

Dr. Giovanni Tazzioli

Oncologic Breast Surgery Unit, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico, 41125 Modena, Italy

Deadline for manuscript submissions

closed (31 July 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).